JC03 Rec'd PCT/PTO 07 JUN 2009

FILING BY "EXPRESS	MAIL" UNDER 37 CFR 1.10
EV 524615665US Express Mail Label Number	Date of Peposit

Form PTO	-1390-MOD U.S.		
(REV 10-96		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER PC/4-32818A
	TRANSMITTAL LETTER TO T	HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
	DESIGNATED/ELECTED O	FFICE (DO/EO/US)	
	CONCERNING A FILING UN		10/537869
	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
	P03/14406 OF INVENTION	17 December 2003 (17.12.03)	18 December 2002 (18.12.02)
	INATIONS OF VALSARTAN WITH CO	DX-2 INHIBITORS	
APPLIC	CANT(S) FOR DO/EO/US		
CAMPI	ION ET AL.		
Applica	nt herewith submits to the United States De	esignated/Elected Office (DO/EO/US) the	ne following items and other information:
1. 🛛	This is a FIRST submission of items cond	cerning a filing under 35 U.S.C. 371.	
2. 3.	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> su	bmission of items concerning a filing un	der 35 U.S.C. 371.
J	examination until the expiration of the ap	plicable time limit set in 35 U.S.C. 371(t	o) and PCT Articles 22 and 39(1).
4. 🛛	A proper Demand for International Prelim date.	inary Examination was made by the 19	th month from the earliest claimed priority
5. 🛛	A copy of the International Application as		
	<ul> <li>a.  is transmitted herewith (required</li> <li>b.  has been transmitted by the Inter</li> </ul>	only if not transmitted by the Internation national Bureau. (See Form PCT/IB/30	nal Bureau).
	c.  is not required, as the application	was filed in the United States Receivin	g Office (RO/US).
6. □ 7. ⊠		ion into English (35 U.S.C. 371(c)(2)).	(35115 C 371(a)(3))
7.	a. are transmitted herewith (require	d only if not transmitted by the Internation	onal Bureau).
	<ul><li>b.  have been transmitted by the Integral</li><li>c. have not been made; however, the</li></ul>	ernational Bureau. ne time limit for making such amendmer	oto hoo NOT overred
	<ul> <li>d.  have not been made and will not</li> </ul>	be made.	·
8. 9.	A translation of the amendments to the cl An executed Declaration and Power of A	laims under PCT Article 19 (35 U.S.C. 3	371 (c)(3)).
- <u>4</u> 9. 🗀	A translation of the annexes to the Internation	ational Preliminary Examination Report	under PCT Article 36 (35 U.S.C.
,	371(c)(5)).		·
	•		•
Items 1	1. to 16. below concern document(s) or	information included.	
11. 🔲	An Information Disclosure Statement und	ler 37 CFR 1.97 and 1.98.	
12. 🔲	An assignment document for recording.	A separate cover sheet in compliance w	vith 37 CFR 3.28 and 3.31 is included.
13. ⊠	A FIRST preliminary amendment.		
	A SECOND or SUBSEQUENT preliminar	ry amendment.	
14. 🛛	An Application Data Sheet under 37 CFR	ł 1.7 <sub>6</sub> .	
15.	A substitute specification.	1	
16. 🗌	A change of power of attorney and/or add	dress letter.	
17.	A computer-readable form of the sequence	ce listing in accordance with PCT Rule	13 <i>ter</i> .2 and 37 CFR 1.821-1.825.
18.	A second copy of the published Internation	onal Application under 35 U.S.C. 154(d)	(4).
19. 🔲	A second copy of the English language to	ranslation of the International application	n under 35 U.S.C. 154(d)(4).
20. 🛛	Other items or information: unsigned dec	claration	

## JC09 Rec'd PCT/PTO 07 JUN 2005,

U.S. APPLICATION NO. (ILKNOW), See 37 CFR 1.5) Q 6 Q INTERNATIONAL APPLICATION NO. PCT/EP03/14406			PC/4-3281	S DOCKET NUMBER 818A						
The following fe	es are si	Ibmitted:						CAL	CULATIO	NS PTO USE
21. 🛭 Basid	21. ⊠ Basic national fee						ONLY			
22. Examination Fee  If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)										
⊠ All of	<u>-</u>						\$200			
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$  If International Search Report was prepared and provided to the Office \$400  All other situations										
TOTAL OF 21, 22 AND 23 =							\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Extra			ch additional 50 or f		R	ATE		-	
49 - 100 =		/50 =		0	5017	X \$	250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than  30 months from the earliest claimed priority date (37 CFR 1.492(e)).							\$			
CLAIMS Total claims		NUMBE 9	R FILED - 20 =	NUMBER EXTR 0	A X	RAT	ΓΕ 50	\$		
Independent cla	ims	6	-3 =	3	X		200	\$	600	
MULTIPLE DEP	ENDEN'	T CLAIM(S)	(if applicable)	TOTAL OF AD	0) (5,0)	<del>-</del>	360	\$	4.500	
TOTAL OF ABOVE CALCULATIONS = \$ 1,500  Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$										
SUBTOTAL =						\$	1,500			
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					n the +	\$				
							AL FEE =	\$	1,500	
Fee for recording by an appropriat	g the end e cover :	closed assig: sheet (37 CF	nment (37 CF FR 3.28, 3.31)	R 1.21(h)). The ass . <b>\$40</b> per property	ignment n	nust be ac	companied +	\$		
by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40</b> per property +  TOTAL FEES ENCLOSED =					LOSED =	\$	1,500			
								be: ı	mount to refunded	\$
-	le in the e				!-				charged	\$
b. 🛛 Please	charge (			to cover the abo			nt of \$1,500 to	o cove	er the abov	re fees. A
c. 🛛 The Co	duplicate copy of this form is enclosed.  c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080  Gregory D. Ferrato/ Attorney for Applicants Reg. No. 36,184 (862) 778-7831										